A 58-year-old woman from Mumbai with Fitzpatrick skin type III presents with multiple nodular lesions on the scalp and face that have been present for 2–3 years. She reports that her father had a similar condition and underwent multiple skin surgeries. On examination, she has firm, skin-colored to slightly erythematous nodules scattered over the scalp, forehead, and cheeks. Histopathology of one lesion shows nests of basaloid cells with peripheral palisading and retraction artifact. What is the most appropriate next step in management?

Explanation

## Management of Multiple Basal Cell Carcinomas: Gorlin Syndrome ### Clinical Context **Key Point:** The presence of multiple BCCs (>5 lesions) in a young patient with a positive family history is highly suggestive of **Gorlin syndrome (Nevoid Basal Cell Carcinoma Syndrome)**, an autosomal dominant condition caused by PTCH1 gene mutations. ### Gorlin Syndrome: Key Features | Feature | Details | |---------|----------| | **Inheritance** | Autosomal dominant (PTCH1 gene mutation) | | **BCC onset** | Often before age 30; multiple lesions (>100 in lifetime) | | **Other skin findings** | Palmar/plantar pits, epidermoid cysts, milia | | **Extracutaneous manifestations** | Odontogenic keratocysts, skeletal abnormalities, CNS tumors (medulloblastoma), cardiac fibromas | | **Cancer risk** | Increased risk of medulloblastoma, rhabdomyosarcoma, meningioma | | **Diagnosis** | Clinical criteria + genetic testing (PTCH1 mutation) | **High-Yield:** Gorlin syndrome accounts for ~1% of all BCCs but is critical to identify because of the systemic manifestations and increased malignancy risk beyond skin. ### Why Genetic Counseling and PTCH1 Testing? 1. **Confirms diagnosis** — PTCH1 mutations are found in >80% of Gorlin syndrome cases 2. **Identifies family members at risk** — allows early screening and surveillance 3. **Guides surveillance protocol** — regular skin exams, imaging for internal malignancies (brain MRI, abdominal ultrasound) 4. **Reproductive counseling** — 50% inheritance risk to offspring 5. **Enables preventive strategies** — sun protection, topical retinoids, systemic retinoid therapy (isotretinoin) in some cases **Clinical Pearl:** Patients with Gorlin syndrome require lifelong multidisciplinary surveillance including dermatology, oncology, and radiology to detect internal malignancies early. ### Management Strategy for Gorlin Syndrome ```mermaid flowchart TD A[Multiple BCCs + Family history]:::outcome --> B{Suspect Gorlin syndrome?}:::decision B -->|Yes| C[Genetic counseling]:::action C --> D[PTCH1 mutation testing]:::action D --> E{Mutation confirmed?}:::decision E -->|Yes| F[Establish surveillance protocol]:::action F --> G[Dermatology: skin exams every 3-6 months]:::action F --> H[Radiology: Brain MRI, abdominal ultrasound annually]:::action F --> I[Treat BCCs: surgical excision, topical/systemic retinoids]:::action E -->|No| J[Standard BCC management]:::action ``` ### Treatment of BCCs in Gorlin Syndrome **Surgical excision** — first-line for accessible lesions **Topical retinoids** — for superficial or multiple lesions (e.g., tretinoin, adapalene) **Systemic retinoids** — isotretinoin (0.5–1 mg/kg/day) for extensive disease; reduces BCC incidence by ~50% but requires careful monitoring (teratogenic, hepatotoxic) **Topical imiquimod** — for select superficial lesions **Vismodegib (Hedgehog pathway inhibitor)** — emerging option for advanced/metastatic BCC or Gorlin syndrome with extensive disease; blocks SMO protein **Key Point:** Observation alone is inappropriate because: - BCCs can become invasive and metastasize (rare but possible) - Systemic manifestations (medulloblastoma, odontogenic keratocysts) require surveillance - Early intervention reduces morbidity **High-Yield:** The Hedgehog signaling pathway is dysregulated in Gorlin syndrome (PTCH1 loss), making it a target for novel therapies like vismodegib.